Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 11/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | PER2 | O15055 | 1/20 | 0.46 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852526 | 0.86 | POLB (0.55) | DRD2DRD3PER2CRY2HTR1A | |
| SCHEMBL18926928 | 0.82 | PRMT5 (0.53) | PRMT5WDR77HTR7DRD2DRD5 | |
| SCHEMBL27719562 | 0.79 | HTR7 (0.50) | PRMT5WDR77HTR7DRD2DRD5 | |
| SCHEMBL8296035 | 0.77 | PRMT5 (0.47) | PRMT5WDR77HTR7DRD2DRD5 | |
| SCHEMBL5113192 | 0.76 | HTR7 (0.53) | PRMT5WDR77HTR7DRD2DRD5 | |
| SCHEMBL30382092 | 0.76 | HTR7 (0.53) | PRMT5WDR77HTR7DRD2DRD5 | |
| SCHEMBL30404097 | 0.76 | HTR7 (0.54) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL578249 | 0.76 | HTR7 (0.54) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL25162957 | 0.75 | HPGD (0.53) | PRMT5WDR77HTR7DRD2DRD5 | |
| Hydrochloric Acid SCHEMBL29877918 | 0.75 | HTR7 (0.51) | PRMT5WDR77HTR7DRD2DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | PRMT5 3632/4885WDR77 3753/4885HTR7 112/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | PRMT5 3632/4885WDR77 3753/4885HTR7 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.